Date: 7th March
Time: 09:30 - 10:45 CET
Organizer: Ana Nordberg on behalf of Nordic PerMed Law
How to register:
Please email email@example.com to register by 6th March. You will receive a Zoom-link shortly before the event.
Counterfeit and Falsified Medicines in the EU is a well-known problem and a topic of great interest to academics, lawyers, medical practitioners, industry and public health authorities. As a topic of research, it is a problem that brings together and lies at the intersection of three spheres of law – medicine, intellectual property (IP), and criminal law.
In this webinar, Associate Professor, Dr. Vishv Priya Kohli (Copenhagen Business School, Denmark) presents and discusses her research with Professor Michael Blakeney (University of Western Australia).
The presentation is based on Dr. Kohli’s recent book ‘Counterfeit and Falsified Medicines in the EU – A Legal Perspective’ (Edward Elgar Publishing, 2021). A work that investigates and highlights key issues such as infiltration of the legal supply chain and the involvement of organised crime, analysing relevant EU law and demonstrating the challenges of CFM. Using examples from several case studies, it reveals gaps in the current legal framework, underlining the particular difficulties created by the interplay between different areas of law; explores areas where improvements have already been made, in particular through the Falsified Medicines Directive; and articulates a number of recommendations.
9:30- 9:40: Welcome speech: ‘The problem of Counterfeit and Falsified Medicines and its relevance for personalised medicine’
By Dr. Ana Nordberg, Associate Professor, Faculty of Law, Lund University, Sweden.
9:40-10:00: ‘Counterfeit and Falsified Medicines in the EU’
Presenter: Dr. Vishv Priya Kohli, Associate Professor, Copenhagen Business School, Denmark.
10:00-10:20: Comments and discussion
Respondent: Professor Michael Blakeney (University of Western Australia).
10:20-10:40: Moderated discussion with the audience
Moderator: Ana Nordberg
10:40-10:45: Closing remarks